Published in Infect Immun on November 01, 2003
Evaluation of IL12B as a candidate type I diabetes susceptibility gene using data from the Type I Diabetes Genetics Consortium. Genes Immun (2009) 0.89
Haplotypes of IL12B promoter polymorphisms condition susceptibility to severe malaria and functional changes in cytokine levels in Thai adults. Immunogenetics (2010) 0.87
Gene-gene interaction and functional impact of polymorphisms on innate immune genes in controlling Plasmodium falciparum blood infection level. PLoS One (2012) 0.83
Sequential Plasmodium chabaudi and Plasmodium berghei infections provide a novel model of severe malarial anemia. Infect Immun (2012) 0.80
Human immune responses to Plasmodium falciparum infection: molecular evidence for a suboptimal THαβ and TH17 bias over ideal and effective traditional TH1 immune response. Malar J (2013) 0.78
CD4+ T cell response correlates with naturally acquired antibodies against Plasmodium vivax tryptophan-rich antigens. Infect Immun (2015) 0.77
Reduced Parasite Burden in Children with Falciparum Malaria and Bacteremia Coinfections: Role of Mediators of Inflammation. Mediators Inflamm (2016) 0.76
Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med (1996) 2.75
Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis (2002) 2.61
Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol (2001) 2.60
Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nat Genet (2001) 2.54
IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. J Immunol (1995) 2.12
IL-12 is required for antibody-mediated protective immunity against blood-stage Plasmodium chabaudi AS malaria infection in mice. J Immunol (2002) 2.00
Low interleukin-12 activity in severe Plasmodium falciparum malaria. Infect Immun (2000) 1.94
A role for CD36 in the regulation of dendritic cell function. Proc Natl Acad Sci U S A (2001) 1.93
IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol (1999) 1.92
Reduced interleukin-12 and transforming growth factor-beta1 in severe childhood malaria: relationship of cytokine balance with disease severity. J Infect Dis (2000) 1.90
Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med (2003) 1.78
Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur J Immunol (1998) 1.42
IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. J Immunol (2001) 1.28
Antibodies to Plasmodium falciparum glycosylphosphatidylinositols: inverse association with tolerance of parasitemia in Papua New Guinean children and adults. Infect Immun (2002) 1.11
A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide production. Genes Immun (2002) 1.07
Changes in cytokine production associated with acquired immunity to Plasmodium falciparum malaria. Clin Exp Immunol (2001) 1.04
Neutrophils and monocytes from subjects with the Mediterranean G6PD variant: effect of Plasmodium falciparum hemozoin on G6PD activity, oxidative burst and cytokine production. Eur Cytokine Netw (1998) 1.03
Blood mononuclear cell nitric oxide production and plasma cytokine levels in healthy gabonese children with prior mild or severe malaria. Infect Immun (1999) 1.02
Modulation of host responses to blood-stage malaria by interleukin-12: from therapy to adjuvant activity. Microbes Infect (2001) 1.02
Increased levels of interleukin-12 in Plasmodium falciparum malaria: correlation with the severity of disease. Parasite Immunol (2002) 0.98
Down-regulation of IL-12 p40 gene in Plasmodium berghei-infected mice. J Immunol (2001) 0.95
Nitric oxide production and mononuclear cell nitric oxide synthase activity in malaria-tolerant Papuan adults. Infect Immun (2003) 0.91
Relationship between plasma Interleukin-12 (IL-12) and IL-18 levels and severe malarial anemia in an area of holoendemicity in western Kenya. Clin Diagn Lab Immunol (2003) 0.89
Systemic nitric oxide production in human malaria. I. Analysis of NO metabolites in biological fluids. Methods Mol Med (2002) 0.81
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet (2009) 16.53
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet (2002) 4.13
New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis (2009) 4.00
The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet (2003) 3.96
Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet (2002) 3.21
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med (2007) 3.13
Artemisinin combination therapy for vivax malaria. Lancet Infect Dis (2010) 3.08
The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis (2008) 3.05
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis (2008) 3.01
The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg (2004) 3.00
Measles: not just another viral exanthem. Lancet (2003) 2.97
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell (2012) 2.96
Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes (2005) 2.85
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A (2008) 2.80
A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet (2002) 2.69
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One (2007) 2.66
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med (2013) 2.65
Person-to-person transmission of severe fever with thrombocytopenia syndrome bunyavirus through blood contact. Clin Infect Dis (2011) 2.59
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother (2002) 2.52
A human type 1 diabetes susceptibility locus maps to chromosome 21q22.3. Diabetes (2008) 2.51
Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood (2009) 2.46
Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J (2008) 2.41
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Trop Med Int Health (2004) 2.36
Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J Infect Dis (2006) 2.26
The Type 1 Diabetes Genetics Consortium. Ann N Y Acad Sci (2006) 2.22
A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis (2012) 2.20
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis (2011) 2.11
Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob Agents Chemother (2007) 2.08
Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium. Diabetes (2009) 2.02
Real-time fluorescence loop mediated isothermal amplification for the diagnosis of malaria. PLoS One (2010) 2.02
Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. Malar J (2008) 2.00
Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. Malar J (2007) 1.97
The metabolic syndrome and CVD outcomes for a central Australian cohort. Diabetes Res Clin Pract (2013) 1.97
Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog (2010) 1.96
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
p47 GTPases regulate Toxoplasma gondii survival in activated macrophages. Infect Immun (2005) 1.93
A real-time PCR-based assay for detection of Wuchereria bancrofti DNA in blood and mosquitoes. Am J Trop Med Hyg (2006) 1.92
The role of biomechanics and inflammation in cartilage injury and repair. Clin Orthop Relat Res (2004) 1.89
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis (2009) 1.86
Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet (2003) 1.86
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
The anaemia of Plasmodium vivax malaria. Malar J (2012) 1.82
Genetics of type 1 diabetes: what's next? Diabetes (2010) 1.80
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood (2010) 1.79
Assessing the effect of natural selection in malaria parasites. Trends Parasitol (2004) 1.78
Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrob Agents Chemother (2009) 1.74
The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis (2008) 1.74
Malaria infections are randomly distributed in diverse holoendemic areas of Papua New Guinea. Am J Trop Med Hyg (2002) 1.73
Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs. Am J Trop Med Hyg (2008) 1.70
Trends in blood pressure and body mass index among Chinese children and adolescents from 2005 to 2010. Am J Hypertens (2013) 1.70
Increasing incidence of Plasmodium knowlesi malaria following control of P. falciparum and P. vivax Malaria in Sabah, Malaysia. PLoS Negl Trop Dis (2013) 1.68
Suicide in the Northern Territory, 1981-2002. Med J Aust (2006) 1.68
Modulation of immune responses during HIV-malaria co-infection in pregnancy. Trends Parasitol (2005) 1.67
Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi. Malar J (2013) 1.66
Is plasma arginine concentration decreased in patients with sepsis? A systematic review and meta-analysis. Crit Care Med (2011) 1.63
Prevalence of type 2 diabetes mellitus of Chinese populations in Mainland China, Hong Kong, and Taiwan. Diabetes Res Clin Pract (2006) 1.61
Pyrosequencing, a high-throughput method for detecting single nucleotide polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum. J Clin Microbiol (2006) 1.61
Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol (2012) 1.59
The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care (2008) 1.59
South American Plasmodium falciparum after the malaria eradication era: clonal population expansion and survival of the fittest hybrids. PLoS One (2011) 1.55
A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax (2010) 1.55
A simple score to predict the outcome of severe malaria in adults. Clin Infect Dis (2010) 1.54
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood (2011) 1.52
Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood (2013) 1.52
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.51
Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother (2008) 1.50
Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int Suppl (2003) 1.50
HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. PLoS Med (2007) 1.49
Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother (2004) 1.48
Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med (2013) 1.48
Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate. Malar J (2012) 1.47
Supramolecular polymerization promoted and controlled through self-sorting. Angew Chem Int Ed Engl (2014) 1.47
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46
Investigating the sustainability of outcomes in a chronic disease treatment programme. Soc Sci Med (2006) 1.46
Granzyme B expression by CD8+ T cells is required for the development of experimental cerebral malaria. J Immunol (2011) 1.46
Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative heterozygotes. PLoS One (2007) 1.45
Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis (2003) 1.44
Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru. Antimicrob Agents Chemother (2007) 1.43
Secular trends of obesity prevalence in urban Chinese children from 1985 to 2010: gender disparity. PLoS One (2013) 1.43
Plasmodium knowlesi malaria in children. Emerg Infect Dis (2011) 1.42
Eosinophils in severe sepsis in northern australia: do the usual rules apply in the tropics? Crit Care Med (2013) 1.42
Pneumonia risk stratification in tropical Australia: does the SMART-COP score apply? Med J Aust (2010) 1.41
Epidemiology of Plasmodium knowlesi malaria in north-east Sabah, Malaysia: family clusters and wide age distribution. Malar J (2012) 1.40
High deformability of Plasmodium vivax-infected red blood cells under microfluidic conditions. J Infect Dis (2009) 1.40
Malaria tolerance--for whom the cell tolls? Trends Parasitol (2006) 1.40
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.39
CD38 variation as a prognostic factor in chronic lymphocytic leukemia. Leuk Lymphoma (2013) 1.39